Showing results (231-240 of 582) with videos related to

Sort By:
Pageof 59
Investigational New Drugs|March 5, 2013
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancerJoanne Brady, Pippa Corrie, Ian Chau, et al.
Leukemia & Lymphoma|November 5, 2021
Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatmentAislinn Macklin-Doherty, Michael Jones, Penny Coulson, et al.
BMC Cancer|April 10, 2024
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 studyElena Elez, Antonio Cubillo, Pilar Garcia Alfonso, et al.
Bjpsych Open|May 17, 2017
In-patient suicide: selection of people at risk, failure of protection and the possibility of causationMatthew Michael Large, Daniel Thomas Chung, Michael Davidson, et al.
Schizophrenia Research. Cognition|June 16, 2025
Cognitive changes in schizophrenia before and after illness onset: A meta-analysis examining consistency in measurement tools as a moderatorNoaz Cohen, Mark Weiser, Abraham Reichenberg, et al.
Schizophrenia Research|January 21, 2012
Do psychiatric registries include all persons with schizophrenia in the general population? A population-based longitudinal studyMark Weiser, Nomi Werbeloff, Bruce P Dohrenwend, et al.
Expert Review of Cardiovascular Therapy|March 25, 2017
The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS studyMichael Davidson, Michael Stevenson, Andrew Hsieh, et al.
Journal of Agricultural and Food Chemistry|April 25, 2014
Self-emulsification of alkaline-dissolved clove bud oil by whey protein, gum arabic, lecithin, and their combinationsYangchao Luo, Yue Zhang, Kang Pan, et al.
Medical Journal (Fort Sam Houston, Tex.)|July 12, 2021
Telemedicine at the Joint Readiness Training Center: Expanding Forward Medical CapabilityMichael D April, Peter J Stednick, Christopher Landry, et al.
Dementia and Geriatric Cognitive Disorders|February 5, 2003
Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 monthsRafael Blesa, Michael Davidson, Alexander Kurz, et al.
Pageof 59